一分钟看懂
这是一项关于肺癌的I 期 / II 期研究，登记的药物或干预包括Telisotuzumab Adizutecan；Budigalimab；Pembrolizumab；Carboplatin；Pemetrexed；Cisplatin，当前状态为招募中。登记地点显示中国北京、福州、柳州、郑州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Telisotuzumab Adizutecan；Budigalimab；Pembrolizumab；Carboplatin；Pemetrexed；Cisplatin · I 期 / II 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录7项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出2项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Cancer Hospital - Chinese Academy of Medical Sciences /ID# 269715 · 北京
- Fujian Province Cancer Hospital /ID# 269150 · 福州
- Liuzhou People's hospital /ID# 269667 · 柳州
- Henan Cancer Hospital /ID# 269668 · 郑州
- Union Hospital - Tongji Medical College /ID# 272286 · 武汉
- Hunan Province Cancer Hospital /ID# 269679 · 长沙
- Nanjing Drum Tower Hospital /ID# 269762 · 南京
- The First Affiliated Hospital of Nanchang University /ID# 269190 · 南昌
- The First Affiliated Hospital of Xi'an Jiaotong University /ID# 271904 · 西安
- Shanghai Chest Hospital /ID# 269155 · 上海
- Shanghai Pulmonary Hospital /ID# 276397 · 上海
- First Affiliated Hospital of Shanxi Medical University /ID# 276482 · 太原
- Sichuan Cancer Hospital /ID# 269712 · 成都
- West China Hospital of Sichuan University /ID# 270244 · 成都
- Yunnan Province Cancer Hospital /ID# 272331 · 昆明
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- * Must have histologically documented non-squamous (NSq) non small cell lung carcinoma (NSCLC) that is locally advanced or metastatic will be enrolled into the study.
- * Must have measurable disease per response evaluation criteria in solid tumors (RECIST) v1.1.
- * For Part 1, participants must have had no more than 1 systemic therapy for advanced disease including platinum-based chemotherapy or an immune checkpoint inhibitor (as monotherapy or in combination with chemotherapy), or appropriate targeted therapy for an actionable gene alteration, if applicable, for epidermal growth factor receptor (EGFR) wild-type (WT) NSq NSCLC.
- * For Part 2, participants must have no prior systemic therapy for advanced disease, no known actionable genomic alteration.
- * Must have documented programmed death ligand 1 (PD-L1) status.
- * For Part 2, participant must have evaluable c-Met immunohistochemistry (IHC) result per central testing prior to randomization.
- * Must have adequate organ function.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06772623；登记信息更新于 2026-10-05；本站同步于 2026-10-08，中国中心当前名额未经人工确认。